Trial · NCT06481696
Possible Action of Resveratrol in Improving the Outcomes of IVF/ICSI in Couples With Unexplained Infertility
NCT06481696, Not applicable, Unknown, Andros Day Surgery Clinic
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Possible Action of Resveratrol in Improving the Outcomes of IVF/ICSI in Couples With Unexplained Infertility. Trials, record NCT06481696. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06481696
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Possible Action of Resveratrol in Improving the Outcomes of IVF/ICSI in Couples With Unexplained Infertility
- NCT number
- NCT06481696
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 90 participants, estimated
- Lead sponsor
- Andros Day Surgery Clinic
- Conditions
- Unexplained Infertility
- Interventions
- Resveratrol-based multivitamin supplement, Folic acid, IVF/ICSI, Follitropin Alfa, Ganirelix Acetate 0.5 MG/ML [Fyremadel], hCG 10.000 IU or triptorelin 0,3 mg, subcutaneously
- First posted
- 2024-07-01
- Last updated
- 2024-07-01
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | FORT (Follicle Output Rate) | The assessment will be performed at the end of stimulation (11°-15° day of a menstrual cycle of 28 days) | It is defined as the ratio of pre-ovulatory follicle (≥ 16 mm in diameter) count (PFC) on the day of induction of oocyte maturation and the antral follicle count at baseline, multiplied by 100 (higher values indicate a better outcome). |
| Primary | FOI (Follicle to Oocyte Index) | The assessment will be performed at the end of oocyte pick up (2 hours after the oocyte pick up) | It is defined by the ratio between the total number of oocytes collected at oocyte pick up and the number of antral follicles at baseline, multiplied by 100. FOI ≤ 50% is considered low (range 0-100%). |
| Primary | The number of mature oocytes | The assessment will be performed after the oocyte pick up (2 hours after the oocyte pick up) | The number of oocytes which have completed the metaphase-II division |
| Primary | OSI (Ovarian Sensitivity Index) | The assessment will be performed at the end of oocyte pick up (2 hours after the oocyte pick up) | It is defined by the ratio between the number of retrieved oocytes and total dose of gonadotropins administered, multiplied by 1000. |
| Secondary | Fertilization rate | The assessment will be carried out the day after the insemination (one day after the oocyte pick up). | The number of embryos obtained after the oocyte insemination. |
| Secondary | Cumulative Clinical Pregnancy Rate | The assessment will be carried out at 7th week of amenorrhea. | It is defined by the ratio between the number of clinical pregnancies (gestational sacs with a fetal heartbeat detected at ultrasound at 7th week of amenorrhea) and the total number of embryo transfers (fresh + frozen) carried out per each patient. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06481696
GET https://conductscience.org/api/trials/v1/NCT06481696/registered